Literature DB >> 3190192

Gentamicin penetration into cerebrospinal fluid in experimental Haemophilus influenzae meningitis.

A L Smith1, R S Daum, G R Siber, D W Scheifele, V P Syriopoulou.   

Abstract

We studied the effect of meningitis and the method of parenteral gentamicin administration (intramuscular injection, a 30-min intravenous infusion, or intravenous bolus administration) on achievable concentrations of drug in cerebrospinal fluid (CSF). In normal animals, only intravenous bolus administration of 2 to 8 mg/kg produced a gentamicin concentration of greater than 0.1 microgram/ml in CSF in some animals. All CSF samples contained less than the limit of detection (0.1 microgram/ml) after the intramuscular administration of 6 mg/kg. In animals with meningitis, gentamicin penetration into cisternal CSF was increased significantly after a bolus administration of 6 mg/kg (mean, 0.197 +/- 0.063 microgram/ml in normal animals versus 1.68 +/- 0.38 micrograms/ml in animals with meningitis; P less than 0.01). In meningitic animals that received 6 mg/kg as an intravenous bolus, lumbar CSF had the highest maximum concentration (4.25 +/- 1.08 micrograms/ml), in comparison with ventricular CSF (3.10 +/- 0.66 micrograms/ml). The gentamicin concentration in cisternal CSF decreased more slowly than it did in serum (elimination half-life, 238.70 +/- 64.56 min in cisternal CSF versus 82.73 +/- 2.91 min in serum), yielding a relative increase in the percentage of penetration. We conclude that maximum penetration by gentamicin into CSF occurs after intravenous bolus administration and that the maximum concentration occurs in lumbar CSF.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3190192      PMCID: PMC172339          DOI: 10.1128/AAC.32.7.1034

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Perfusion of particles through arachnoid villi of the monkey.

Authors:  K WELCH; M POLLAY
Journal:  Am J Physiol       Date:  1961-10

2.  Gentamicin in newborn infants. Comparison of intramuscular and intravenous administration.

Authors:  J W Paisley; A L Smith; D H Smith
Journal:  Am J Dis Child       Date:  1973-10

3.  Ventriculitis complicating meningitis.

Authors:  J H Salmon
Journal:  Am J Dis Child       Date:  1972-07

4.  Relationship of intraventricular gentamicin levels to cure of meningitis. Report of a case of Proteus meningitis successfully treated with intraventricular gentamicin.

Authors:  R C Moellering; E G Fischer
Journal:  J Pediatr       Date:  1972-09       Impact factor: 4.406

5.  Some observations on dosage and toxicity of kanamycin in premature and full-term infants.

Authors:  H F Eichenwald
Journal:  Ann N Y Acad Sci       Date:  1966-06-14       Impact factor: 5.691

6.  Aminoglycoside therapy of gram-negative bacillary meningitis.

Authors:  A B Kaiser; Z A McGee
Journal:  N Engl J Med       Date:  1975-12-11       Impact factor: 91.245

7.  Physiological studies on the development of obstructive hydrocephalus in the monkey.

Authors:  V A Levin; T H Milhorat; J D Fenstermacher; M K Hammock; D P Rall
Journal:  Neurology       Date:  1971-03       Impact factor: 9.910

8.  Penetration of parenterally administered gentamicin into the cerebrospinal fluid in experimental meningitis.

Authors:  K Goitein; J Michel; T Sacks
Journal:  Chemotherapy       Date:  1975       Impact factor: 2.544

9.  The transport of gentamicin in the choroid plexus and cerebrospinal fluid.

Authors:  R Spector
Journal:  J Pharmacol Exp Ther       Date:  1975-07       Impact factor: 4.030

10.  Pharmacokinetics of gentamicin in children and adults.

Authors:  G R Siber; P Echeverria; A L Smith; J W Paisley; D H Smith
Journal:  J Infect Dis       Date:  1975-12       Impact factor: 5.226

View more
  6 in total

1.  Long-term nonsense suppression therapy moderates MPS I-H disease progression.

Authors:  Gwen Gunn; Yanying Dai; Ming Du; Valery Belakhov; Jeyakumar Kandasamy; Trenton R Schoeb; Timor Baasov; David M Bedwell; Kim M Keeling
Journal:  Mol Genet Metab       Date:  2013-12-17       Impact factor: 4.797

2.  The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse.

Authors:  Dan Wang; Valery Belakhov; Jeyakumar Kandasamy; Timor Baasov; Su-Chen Li; Yu-Teh Li; David M Bedwell; Kim M Keeling
Journal:  Mol Genet Metab       Date:  2011-10-19       Impact factor: 4.797

Review 3.  Suppression of premature termination codons as a therapeutic approach.

Authors:  Kim M Keeling; Dan Wang; Sara E Conard; David M Bedwell
Journal:  Crit Rev Biochem Mol Biol       Date:  2012-06-07       Impact factor: 8.250

Review 4.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

5.  Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation.

Authors:  Dan Wang; Charu Shukla; Xiaoli Liu; Trenton R Schoeb; Lorne A Clarke; David M Bedwell; Kim M Keeling
Journal:  Mol Genet Metab       Date:  2010-01       Impact factor: 4.797

6.  Gentamicin-loaded nanoparticles show improved antimicrobial effects towards Pseudomonas aeruginosa infection.

Authors:  Sharif M Abdelghany; Derek J Quinn; Rebecca J Ingram; Brendan F Gilmore; Ryan F Donnelly; Clifford C Taggart; Christopher J Scott
Journal:  Int J Nanomedicine       Date:  2012-07-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.